Navigation Links
Growth Achieved in Spherix's Health Sciences Consulting Business
Date:11/29/2007

Phase 3 Clinical Trial on Track, Market Research Contracts Signed

BELTSVILLE, Md., Nov. 29 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) has recently signed contracts to provide technical and regulatory consulting services to several major consumer, food, ingredient, and pharmaceutical companies. Spherix's Health Sciences Consulting Division provides scientific and strategic support for suppliers, manufacturers, distributors, and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides.

"I am very pleased with the progress made in our Health Sciences Division," said Claire Kruger, CEO and Director of Health Sciences of Spherix. "Revenues earned through these efforts will add to our substantial cash reserve, and will be very useful moving forward."

The Company further reported that its Phase 3 clinical trial of Naturlose(R) as a treatment for Type 2 diabetes is progressing on schedule. Since moving the entire study to the United States, patient recruitment has increased and, logistically, everything is moving ahead much more efficiently. The protocol for the Company's dose ranging study has been finalized and is scheduled to begin later this year. An additional study to determine if Naturlose will work with only one dose per day is being finalized, and it is hoped that this study will begin early next year. Results from a recent trial evaluating efficacy of tagatose in toothpaste that was conducted at the University of Maryland did not show significant activity; further trials for this endpoint are being halted to focus on the diabetes market.

The diabetes drug market is now changing rapidly due to major product withdrawals. In the next strategic step forward in an effort to commercialize Naturlose as a drug to treat diabetes, contracts have been signed with two pharmaceutical market research firms to analyze the current market for Type 2 diabetes drugs and help to position Naturlose within that product space. In addition, primary market research will be conducted under these contracts with physicians and patients to determine the impact of new formulations and dosing regimens, and distributors will be surveyed to package the drug in the optimal form.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is http://www.spherix.com.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
2. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
3. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
4. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
5. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Tone Deafness Explained, from the Harvard Health Letter
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):